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Introduction 
 
Klebsiella pneumoniae is an important causative 
agent of hospital-acquired infections, including 
severe pneumonia, urinary tract infection as well 
as septicemia and wound infections (1, 2). This 
bacterium can survive in hospitals, persist on 
environmental surface and colonize different 
parts of human body. Therefore, transmission of 
this opportunistic pathogen can easily occur 
among patients via the hands of healthcare per-
sonnel. Furthermore, the increased use of antibi-
otics and persistent exposure of K. pneumoniae to a 
number of antimicrobial agents, facilitating the 
emergence of multidrug-resistant strains, which 
has further intensified the infection control strat-
egies in many health care settings (3).  
The most important resistant isolates of K. 
pneumoniae are carbapenem and cephalosporin 
resistant strains (4). These strains can cause seri-
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ous infections in immunocompromised patients, 
in association with prolonged hospital, stays, lim-
ited therapeutic options and increased mortality 
rates, ranging from 12% to as high as 72%, de-
pending on the study population (5-9). In these 
regards, a reliable estimate of the extent of drug 
resistant isolates of K. pneumoniae is needed for 
the programmatic management of drug resistant 
strains within the context of national infection 
control programs.  
This study was designed to determine the preva-
lence of drug resistant strains of K. pneumoniae in 
Iran according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses 
statement (10, 11).  
 
Methods  
 
Search strategies 
We conducted the search using PubMed, Web of 
Science, Cochrane library and Scopus for all stud-
ies addressing the prevalence of drug resistant 
strains of K. pneumoniae in Iran, from Jan 1998 to 
Nov 2014. The applied keywords include Klebsiel-
la, Klebsiella pneumoniae, antibiotic resistance, anti-
biotic susceptibility, and Iran. Iranian databases 
including Iranmedex and Scientific Information 
Database (SID) were also searched (with Persian 
keywords). 
 
Inclusion and exclusion criteria 
We considered all the original articles about the 
incidence rate of drug resistant strains of K. 
pneumoniae from hospital-acquired infections in 
Iran. These articles should reference to the stand-
ard method, which recommended by clinical and 
laboratory standards Institute (CLSI) for drug 
susceptibility testing of K. pneumoniae against; car-
bapenems, cephalosporins and the other most 
used antimicrobial agents. Due to the follow-
ing reasons, some studies were excluded from 
our analysis. Articles have focused only on com-
munity acquired K. pneumoniae or focused only on 
non-K. pneuomoniae stains, and studies not used 
CLSI recommended drug susceptibility testing 
methods. Furthermore, case reports, meta-
analyses or systematic reviews, letters to editor, 
review articles, non-English or Persian studies, 
and duplicate publication, were also excluded. 
 
Data extraction and deﬁnitions 
The extracted data in current study include the 
first author’s name, the publication time, year of 
study, number of samples, and prevalence of 
drug resistant strains of K. pneumoniae. Two au-
thors extracted data from all of the included stud-
ies independently and a third investigator re-
viewed results. 
 
Statistical analysis 
The comprehensive meta-analysis software (ver. 
2.0) was used to analyse the data. Because of the 
heterogeneity between studies, random effects 
models were used and tested with the Cochrane 
Q test. Moreover, Egger weighted regression and 
Begg rank correlation tests were performed to 
assess possible publication bias. 
 
Results 
 
Initially, 1353 articles were collected (Fig. 1). 
However, in a secondary screening, 1308 of them 
were excluded according to duplication, title, and 
abstract evaluation, and full-text of 45 papers was 
evaluated. Finally, 27 articles describing the prev-
alence of the ceftazidime- and/or imipenem- re-
sistant strains of K. pneumoniae were selected for 
meta-analysis (Table 1). In all included studies, 
antimicrobial susceptibility testing had been per-
formed using disc diffusion method as recom-
mended by CLSI guidelines. Most of the studies 
were done in Tehran (n=11) compared with Isfa-
han (n=4), Fars (n=3), East Azerbaijan (n=2), 
Semnan (n=2), Hamadan (n=2), K. Boyer Ah-
mad (n=1), West Azerbaijan (n=1) and Kerman 
(n=1). Fig. 2 shows the distribution of drug-
resistant strains of K. pneumoniae in different re-
gions of Iran. The prevalence of imipenem and 
ceftazidime resistance was found to be 3.2% 
(95% CI, 1.5-6.5) and 55.7% (95% CI, 46.9-64.1), 
respectively (Table 2). Fig. 3 and 4 show the for-
est plot of the Meta-analysis of imipenem and 
ceftazidime resistant K. pneumoniae.  
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Table 1: Included studies after full-text evaluation 
 
 
References 
 
 
Published 
time 
 
Enroll-
ment 
time 
 
Province 
Total number 
of samples 
Isolates 
of 
Klebsiella penomoniae 
Number of Resistance to 
Ceftazidime 
(%) 
Imipenem 
(%) 
  
12 2007 2002-2005 Tehran 200 33 24(73) - 
13 2005 2003-2004 Tehran 115 100 28(28) 0(0) 
14 2011 2006-2009 Tehran 250 250 95(38) 3(1) 
15 2010 2007-2008 Tehran 101 25 23(92) 2(8) 
16 2008 2007-2008 Tehran 164 40 20(50) - 
17 2009 2007-2008 Tehran 65 30 23(77) 0(0%) 
18 2010 2008-2009 Tehran 81 62 53(85) 0(0%) 
19 2014 2009-2010 Tehran 50 30 26(87) - 
20 2013 2009-2011 Tehran 360 45 34(76) 3(7) 
21 2014 2011-2012 Tehran 83 83 46(55) 20(24) 
22 2012 2011-2012 Tehran 120 45 21(47) - 
23 2011 2009-2010 Isfahan 211 30 7(23) - 
24 2014 2013-2014 Isfahan 123 15 - 0(0) 
25 2011 2009-2010 Isfahan 167 36 23(64) 0(0) 
26 2013 2010-2011 Isfahan 61 61 30(49) - 
27 2013 2009-2010 Fars 571 60 28(47) 1(2) 
28 2012 2009-2010 Fars 328 144 - 12(8) 
29 2013 2009-2010 Fars 60 60 28(47) 1(2) 
30 2008 2007-2008 East 
Azarbaijan 
88 47 43(91) 0(0) 
31 2010 2008-2009 East 
Azarbaijan 
72 72 58(81) - 
32 2010 2007-2008 Semnan 310 76 18(24) - 
33 2009 2007-2008 Semnan 382 107 21(20) - 
34 2014 2007-2008 Kerman 413 75 52(69) 2(3) 
35 2005 1999-2001 West 
Azarbaijan 
251 19 3(16) - 
36 2013 2010-2012 Kohgiluyeh 
and 
Boyer Ahmad 
202 180 93(52) - 
37 2013 2011-2012 Hamedan 120 120 44(37) 0(0) 
38 2009 2004-2006 Hamedan 209 30 - 2(7) 
 
Table 2: The prevalence of imipenem and ceftazidime resistance among Klebsiella pneumoniae 
  
Subgroups No. of 
study 
Prevalence of 
drug resistance 
(95% CI) 
n/N* Heterogeneity Test Egger’s test for publi-
cation bias 
  
I2 (%) P-value t P-value 
        
Overall effects of resistant 
to imipenem 
16 3.2 (1.5-6.5) 46/1182 75.9 <.001 5.1 0.00016 
Overall effects of resistant 
to ceftazidime 
24 55.7 (46.9-64.1) 841/1686 92.2 <.001 2.4 0.02454 
CI, confidence interval; n, number of events (drug resistance); N, total number of Klebsiella pneumoniae from the in-
cluded studies 
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Fig. 1: Summary of the literature search and study selection 
 
Some evidence for publication bias for imipenem 
and ceftazidime was observed (P<0.05 for Begg 
rank correlation analysis; P<0.05 for Egger 
weighted regression analysis) (Fig. 5, 6). The 
resistance of K. pneumoniae to other important an-
timicrobial agents is shown in Table 3. 
 
 
 
Fig. 2: Distribution of drug-resistant Klebsiella pneumoniae in different regions of Iran 
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Table 3: Drug resistance status in Klebsiella pneomoniae 
 
Refer-
ences 
 
Enrollment 
time 
Case 
num
ber 
Car-
bapenem 
Cephalosporins Aminogly-
cosides 
Fluoroquin-
olones 
Mono-
bactam 
Peni-
cillins 
Mac-
rolid 
Cotri-
moxazole 
IM
P 
1 
ME
M 
2 
CA
Z3 
CT
X4 
CR
O5 
CP
M 
6 
AM
K7 
GM 
8 
CIP 
9 
AZT 
10 
AMP 
11 
NF 
12 
TMP/SX
T 
13 
12 2002-2005 33 - - 24 19 19 - 14 21 15 26 - 14 - 
13 2003-2004 100 0 - 28 - 20 - 9 30 20 - - 31 - 
14 2006-2009 250 3 - 95 91 86 100 53 82 85 - - - - 
15 2007-2008 25 2 - 23 22 23 22 24 - 17 - 24 13 18 
16 2007-2008 40 - - 20 - 19 - 8 14 12 - 40 16 20 
17 2007-2008 30 0 - 23 6 20 25 20 16 18 - 30 18 18 
18 2008-2009 62 0 - 53 56 47 44 14 30 32 59 - 16 47 
19 2009-2010 30 - - 26 25 - - 16 17 26 - 30 - - 
20 2009-2011 45 3 13 34 37 - 33 11 - 32 32 - - 38 
21 2011-2012 83 20 20 46 50 49 30 12 29 46 49 65 - - 
22 2011-2012 45 - - 21 - - - - - 43 - - 23 31 
23 2009-2010 30 - - 7 5 - - 0 7 6 - 21 10 8 
24 2013-2014 15 0 0 - 15 - 15 8 - 12 - 15 10 - 
25 2009-2010 36 0 - 23 21 - 22 12 - 13 - 33 7 28 
26 2010-2011 61 - - 30 49 37 - - - - - - - - 
27 2009-2010 60 1 - 28 34 - 29 5 8 13 19 60 - 26 
28 2009-2010 144 12 - - - - - 61 65 42 - 23 - 43 
29 2009-2010 60 1 - 28 34 - 29 5 8 13 19 60 - 26 
30 2007-2008 47 0 - 43 42 44 39 5 - - 41 - - - 
31 2008-2009 72 - - 58 - - - 31 53 31 - - 68 69 
32 2007-2008 76 - - 18 19 - - - 19 35 - 73 - 41 
33 2007-2008 107 - - 21 24 - - - 19 21 - 97 - 27 
34 2007-2008 75 2 - 52 25 - 27 - 48 21 - - - 35 
35 1999-2001 19 - - 3 - - - 0 5 3 - 14 - 3 
36 2010-2012 180 - 41 93 87 81 - 40 65 31 83 - 138 108 
37 2011-2012 120 0 - 44 50 52 30 - 32 20 52 - - 49 
38 2004-2006 30 2 - - - 3 3 11 13 7 19 60 - - 
Mean 
Rate 
- - 46 
(3.2) 
74 
(18.9) 
841 
(55.7) 
711 
(49.9) 
500 
(47.1) 
448 
(47.8) 
359 
(25.8) 
581 
(36.3) 
613 
(34.8) 
399 
(55.4) 
645 
(82.2) 
364 
(54.5) 
635 
(51.8) 
Abbreviations: 1. IMP, imipenem; 2. MEM, meropenem; 3.CAZ, ceftazidime; 4. CTX, cefotaxime; 5. CRO, ceftrixone; 6. CPM, cefepime; 7. 
AMK, amikacin; 8. GM, gentamycin; 9.CIP, ciprofloxacin; 10. AZT, aztreonam; 11. AMP, ampicillin; 12. NF, nitrofurantoin; 13.SXT/TMP, 
trimethoprim/sulfamethoxazole 
 
 
 
Fig. 3: Forest plot of the meta-analysis on imipenem resistance. CI, conﬁdence interval 
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Fig. 4: Forest plot of the meta-analysis on ceftazidime resistance. CI, conﬁdence interval 
 
 
 
Fig. 5: Funnel plot of the meta-analysis on imipenem resistance 
 
 
 
Fig. 6: Funnel plot of the meta-analysis on ceftazidime resistance 
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Discussion 
 
The emergence and spread of carbapenem and 
cephalosporin resistant strains of K. pneumoniae 
are a considerable threat to public health (2). The 
major goal of this systematic review was to evalu-
ate the current situation and distribution of drug-
resistant K. pneumoniae in Iran.  
This analysis showed that 3.2% K. pneumoniae iso-
lates from Iran was resistant to imipenem and 
55.7% to ceftazidime. Thereby despite 
ceftazidime, the imipenem remains as a powerful 
weapon against K. pneumoniae isolates in Iran. In 
the current study more than half of K. pneumoniae 
isolates were resistant to other important antimi-
crobial agents such as aztreonam (55.4 %), nitro-
furantoin (54.5%) and co-trimoxazole (51.8%), 
we highly recommend that antimicrobial test 
should be performed prior to any antibiotic pre-
scription in K. pneumonia infections. Very low 
number of K. pneumonia population (17.8%) were 
sensitive to ampicillin suggesting ampicillin is not 
effective drug for empiric treatment of K. pneumo-
nia infections unless we use it in combination with 
other relevant drugs.  
The relatively high rates of drug resistant isolates 
of K. pneumoniae observed in this study may have 
several negative effects on public health issues 
(39). For example, this could cause difficulty in 
treating K. pneumoniae associated infections since 
fewer effective drugs are available for treating 
those highly drug-resistant strains.  Unfortunate-
ly, these microorganisms are even showing rising 
rates of resistance to new expensive antibiotics 
subsequently considered the treatment of choice 
(40). This is due to the widespread use of broad-
spectrum antibiotics in health care settings for 
empiric treatment of infections. Furthermore, 
patients infected with these pathogens require 
prolonged antimicrobial therapy that has consid-
erable implications for the individual patient and 
for the health care settings. Finally, infections due 
to these highly resistant strains are reported to be 
associated with higher morbidity and mortality 
rates (41). In Iran, 50000 people die each year 
because of multidrug-resistant bacterial infections 
and that this costs Iranian economy 2.5 million 
dollars annually (4).  
Some important reasons for the increasing rates 
of drug resistant isolates in Iran include limited 
infection surveillance programs, the lack of 
communication between physicians and microbi-
ologists, lack of standardized or accepted criteria 
to determine drug resistant isolates, limited labor-
atory facilities, and poor sanitation. Therefore, 
active infection control committee, appropriate 
antimicrobial therapy, and improvement of hy-
giene condition will prevent or lower the emer-
gence of antimicrobial-resistant pathogens (42).  
Current review was carried out according to 
provinces of Iran and the published time. Be-
cause of many hospitals and health care centers 
in Tehran Province, Iran, patients from other 
provinces come to Tehran for better treatment. 
Therefore, most of the studies in this analysis 
belonged to Tehran, where the ceftazidime- 
and/or imipenem- resistant strains of K. 
pneumoniae mostly reported by researchers. 
 
Conclusion 
 
There is a relatively high prevalence of drug re-
sistant K. pneumoniae isolates in Iran. Thus, a high 
degree of awareness among physicians and mi-
crobiologists, active infection control committee, 
appropriate antimicrobial therapy, improvement 
of hygiene condition and monitoring of drug re-
sistant isolates are urgently needed in order to 
better control the emergence and spread of drug-
resistant K. pneumoniae isolates in hospital settings. 
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